Dynavax Technologies (NASDAQ:DVAX) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.
Profitability
This table compares Dynavax Technologies and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Dynavax Technologies | -256.92% | -193.85% | -23.45% |
| Regeneron Pharmaceuticals | 38.28% | 28.97% | 20.11% |
Risk & Volatility
Dynavax Technologies has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Dynavax Technologies and Regeneron Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Dynavax Technologies | 0 | 0 | 4 | 0 | 3.00 |
| Regeneron Pharmaceuticals | 0 | 5 | 14 | 1 | 2.80 |
Dynavax Technologies presently has a consensus target price of $16.3333, suggesting a potential upside of 62.20%. Regeneron Pharmaceuticals has a consensus target price of $637.2083, suggesting a potential upside of 34.77%. Given Dynavax Technologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe Dynavax Technologies is more favorable than Regeneron Pharmaceuticals.
Earnings and Valuation
This table compares Dynavax Technologies and Regeneron Pharmaceuticals' revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Dynavax Technologies | $35.22 million | 32.38 | $-152,600,000.00 | ($1.87) | -5.39 |
| Regeneron Pharmaceuticals | $7.86 billion | 6.44 | $2.12 billion | $21.47 | 22.02 |
Regeneron Pharmaceuticals has higher revenue and earnings than Dynavax Technologies. Dynavax Technologies is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
80.0% of Dynavax Technologies shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 13.3% of Dynavax Technologies shares are held by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Regeneron Pharmaceuticals beats Dynavax Technologies on 10 of the 15 factors compared between the two stocks.
